Novavax swings to profit in Q4 CEO remains optimistic despite U.S. regulatory uncertainties Shares surge over 22% after strong results Feb 26 (Reuters) - Novavax (NVAX.O), opens new tab raised its ...

Novavax reported fourth-quarter earnings of 11 cents, a shift from a loss of 51 cents a year ago. evenue for the fourth quarter was $147 million, a 67% year-over-year increase. Novavax on Thursday ...

2024-2025 COVID-19 vaccines reduced hospitalization risk by 40% against JN.1 lineage variants. COVID-19 is still a public threat and health concern. Between 2024 and 2025, an estimated 380,000 to ...

European drug regulators recommended authorizing Moderna’s combined vaccine against Covid-19 and the flu, paving the way for the shot’s approval in the European Union at a time the company is facing ...

A federal court injunction put a check on Health Secretary Robert F. Kennedy Jr.'s rapid assault on U.S. vaccine recommendations, but months of turmoil and misinformation have sown doubt about ...

Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, banking on milestone payments from licensing and supply deals for its shots, although it noted that the current ...

Feb 27 (Reuters) - Europe's medicines regulator recommended approval for Moderna's COVID and flu combination vaccine on Friday, putting it on track to become the ‌first single shot to protect people ...

Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...

The Food and Drug Administration (FDA) will review Moderna's application for its new flu vaccine, marking a resolution to a dispute that had previously stalled the process. This innovative vaccine ...